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OBJECTIVE—We used a single nucleotide polymorphism
(SNP) map in a large cohort of 580 African American families to
identify regions linked to type 2 diabetes, age of type 2 diabetes
diagnosis, and BMI.
RESEARCH DESIGN AND METHODS—After removing outli-
ers and problematic samples, we conducted linkage analysis
using 5,914 SNPs in 1,344 individuals from 530 families. Linkage
analysis was conducted using variance components for type 2
diabetes, age of type 2 diabetes diagnosis, and BMI and nonpara-
metric linkage analyses. Ordered subset analyses were con-
ducted ranking on age of type 2 diabetes diagnosis, BMI, waist
circumference, waist-to-hip ratio, and amount of European ad-
mixture. Admixture mapping was conducted using 4,486 markers
not in linkage disequilibrium.
RESULTS—The strongest signal for type 2 diabetes (logarithm
of odds [LOD] 4.53) was a broad peak on chromosome 2, with
weaker linkage to age of type 2 diabetes diagnosis (LOD 1.82).
Type 2 diabetes and age of type 2 diabetes diagnosis were linked
to chromosome 13p (3–22 cM; LOD 2.42 and 2.46, respectively).
Age of type 2 diabetes diagnosis was linked to 18p (66 cM; LOD
2.96). We replicated previous reports on chromosome 7p (79 cM;
LOD 2.93). Ordered subset analysis did not overlap with linkage
of unselected families. The best admixture score was on chro-
mosome 12 (90 cM; P  0.0003).
CONCLUSIONS—The linkage regions on chromosomes 7
(27–78 cM) and 18p overlap prior reports, whereas regions on 2p
and 13p linkage are novel. Among potential candidate genes
implicated are TCF7L1, VAMP5, VAMP8, CDK8, INSIG2, IPF1,
PAX8, IL18R1, members of the IL1 and IL1 receptor families, and
MAP4K4. These studies provide a complementary approach to
genome-wide association scans to identify causative genes for
African American diabetes. Diabetes 58:268–274, 2009
T
ype 2 diabetes is marked by a clear genetic
propensity, a high concordance in identical
twins, tendencies for both diabetes and age of
onset to be familial (1), and marked differences
in prevalence among ethnic groups (2). Despite consider-
able evidence for a genetic predisposition, unraveling the
genetic etiology has been daunting, with few conﬁrmed
genes identiﬁed from genome-wide linkage scans. Recent
successes with genome-wide association scans (3) have
greatly increased the number of conﬁrmed genetic loci,
but these successes have been limited primarily to Cauca-
sian populations. With few exceptions (TCF7L2), these
regions from genome-wide association scans overlap nei-
ther with published linkage scans nor with known candi-
date genes or pathways, and in many cases, the variants
are of unknown functional signiﬁcance. These conﬁrmed
diabetes genes are uniformly of small effect size, and
together, they explain only a small portion of diabetes risk
even in Caucasians (4). Only variants at TCF7L2 show
evidence for an association in African American popula-
tions (5), but the association of TCF7L2 with diabetes and
reduced insulin secretion has not been easily reproducible
(6). Thus, the genetic predisposition for type 2 diabetes in
minority populations remains largely unknown. Particu-
larly for African-based populations, low levels of linkage
disequilibrium increase the challenge of mapping genes by
genome-wide association and argue for the importance of
complementary methods.
Previous genome-wide linkage scans for type 2 diabetes
in African American or African families have been limited.
A small African American sample of 229 individuals (124
sibpairs) was included in the original microsatellite link-
age scan of GENNID (Genetics of NIDDM) Study families
(7) and showed linkage on chromosome 10 near microsat-
ellite marker D10S1412. Sale et al. (8) examined 392
microsatellite markers in 675 individuals (638 affected
sibpairs) and reported suggestive linkage on chromosome
6 near D6S1035 (163.5 cM); other regions on 7p showed an
association with earliest onset diabetes. Rotimi et al. (9)
examined 390 microsatellite markers in 691 individuals
(343 affected sibpairs) from West Africa and found evi-
dence for linkage on chromosomes 20q13.3 and 12q24.
Studies of single nucleotide polymorphism (SNP)-based
linkage scans have not been published. In contrast to
Caucasian linkage scans, the few available studies of
African-derived populations have not replicated regions of
linkage.
From 1993 to 2003, the American Diabetes Association
sponsored the collection of families and sibpairs with at
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Study (10). The families were collected in three phases.
Phase 1 (1993–1995) included multiplex families, but only
one site (University of Chicago) contributed African Amer-
ican families. In 1995, criteria were changed to nuclear
families, and subsequently, ascertainment was further
expanded with four new sites for African American fami-
lies. Hence, the sample set was expanded considerably
beyond the earlier analysis of Ehm et al. (7). In the present
study, we examined 1,496 individuals from 580 pedigrees
ascertained at 10 centers and providing 1,021 sibpairs with
genotypes. This study with 5,619 SNP markers is thus the
largest study of type 2 diabetes genetics in families of
African descent to date.
RESEARCH DESIGN AND METHODS
African American subjects were ascertained and tested using the protocols
and procedures of the GENNID project, as described previously (10), from 10
sites: Birmingham, AL; Little Rock, AR; Chicago; Denver, CO; Los Angeles
(two sites); Baltimore, MD; Raleigh-Durham, NC; Charleston, SC; and St.
Louis, MO (Table 1). Pedigrees were ascertained between 1993 and 2003 in
three phases, all requiring two affected siblings. Phase 1 included multigen-
erational families ascertained in Chicago. Phase 2 included nuclear families
with affected siblings, parents if available, or unaffected siblings where both
parents were not available. Phase 3 included affected sibpairs. The distribu-
tion of individuals and sibpairs by site is listed in Table 1. Age of diagnosis was
obtained by history using a standardized questionnaire (10). Physical exami-
nation data and DNA were available on 1,496 individuals from 580 pedigrees
(Table 1). After removal of apparent sample discrepancies, the sample was
reduced to 1,450 individuals, of whom 73 were the only members of the
families and 9 were unrelated to any other pedigree member. Additional
samples were removed subsequently for missing diabetes status (n  2),
missing current age (n  1), age of diagnosis reported 15 years (n  36), or
BMI 14 or 55 kg/m
2 (n  65). Relationships included 1,021 full sibpairs
and are shown in supplementary Table S1, available in an online appendix at
http://dx.doi.org/10.2337/db08-0931. For the analyses reported, we included
1,082 affected individuals for sibpair analyses and variance component
analysis with age of type 2 diabetes diagnosis and 1,344 individuals for
analysis of BMI and type 2 diabetes.
DNA preparation and genotyping. DNA was prepared from lymphoblastoid
cell lines by Coriell Cell Repository (Camden, NJ) by salting out; DNA quality
was checked by pico-green, and concentration was adjusted for submission to
the Center for Inherited Disease Research (CIDR). Genotyping was completed
using the Illumina Golden Gate assay to type Illumina Linkage Panel IVb,
comprising 6,008 SNPs, of which 5,958 were released. Data were analyzed
using the Illumina BeadStudio Genotyping Module, v2.3.41.
Quality control and error corrections. CIDR reported 0.22% missing
genotypes and 99.926% Mendelian consistency. Concordance between 66 blind
duplicates was 99.9985%. Pedigree structures were examined for 1,413 SNPs
selected for spacing at 2 cM using the Eclipse2 program (11). Likelihoods of
eight relationships (monozygotic twins, full siblings, half siblings, parent-
offspring, avuncular, grandparent-grandchild, and unrelated) were calculated.
Two pairs of monozygotic twins were identiﬁed, 11 individuals were removed
due to apparent sample mix-ups, and 89 families with nonpaternity or
nonmaternity were identiﬁed and corrected. An additional eight pedigrees
were merged based on likelihoods supporting ﬁrst- or second-degree relation-
ships between pairs of pedigrees from the same site. Resulting corrections
reduced the sample size to 1,450 members of 534 pedigrees, for which 4,004
genotypes (0.047%) were missing. Genotyping errors were identiﬁed using
Pedcheck (12) to remove family members with Mendelian inconsistencies and
MERLIN (13) to identify markers with excess recombination. These steps
removed 6,435 genotypes (0.075% of the total). For seven markers, 5–10% of
genotypes were missing. An additional 37 SNPs showed deviations from
Hardy-Weinberg equilibrium at P  0.005, and 31 showed deviations with
0.005  P  0.01. Removal of these possibly poor-quality SNPs had minimal or
no effect on logarithm of odds (LOD) scores (data not shown).
Statistical analysis. We conducted linkage analysis using variance compo-
nent likelihood analysis for the traits type 2 diabetes, type 2 diabetes age of
diagnosis/onset, and BMI and nonparametric linkage (NPL) analysis imple-
mented in MERLIN (13) for type 2 diabetes. We report variance component
linkage analysis using 5,914 markers and NPL analyses using 5,870 markers.
For variance component analysis, we used a likelihood analysis implemented
in jPAP (14). Sample size was 1,344 for type 2 diabetes and BMI and 1,082 for
age of type 2 diabetes diagnosis. Detailed methods are provided in supple-
mental materials in the online appendix. Brieﬂy, we modeled type 2 diabetes
risk to account for age of type 2 diabetes diagnosis in affected pedigree
members using a modiﬁcation of the age at diagnosis regressive model
described elsewhere (15). We modeled the logit probability of type 2 diabetes
on age, BMI, and sex. Both age of type 2 diabetes diagnosis and BMI were
modeled as a normal density with mean  SD. Linkage was tested using
multipoint identity by descent probabilities computed in MERLIN (13) and by
comparing the maximized likelihood with a quantitative trait locus (QTL) to
that without the QTL. The LOD score was calculated as the common logarithm
of the likelihood ratio. NPL was calculated using MERLIN with NPL and
S-Pairs statistics. We present best ﬁndings from all three methods; the NPL
score gave more conservative results.
Linkage disequilibrium between SNPs could inﬂate LOD scores for linkage
studies. To address this issue, SNPs were clustered using r
2 thresholds of 0.25,
0.50, and 0.70, as implemented in MERLIN, assuming no recombination within
clusters and no linkage disequilibrium between clusters. Using the three
thresholds, we identiﬁed 338 SNPs in 147 clusters (r
2  0.7), 462 SNPs in 202
clusters (r
2  0.5), and 770 SNPs in 332 clusters (r
2  0.25). The different
thresholds had little effect on LOD scores (data not shown); we present results
when correcting for clusters of SNPs with r
2  0.7.
Ordered subset analysis was conducted using family-speciﬁc LOD scores
from the MERLIN output for both NPL and S-Pairs statistics. Families were
ranked from low to high and from high to low based on average-within-family
values for age of type 2 diabetes diagnosis, BMI, waist circumference,
waist-to-hip ratio (WHR), diabetes duration, and admixture. The maximum
LOD score was calculated using the program FLOSS (16). Signiﬁcant differ-
ences from the unranked LOD score were calculated based on a minimum of
500 permutations with ranks randomly assigned.
Association of each marker was calculated using the regression models
described above and comparing the model with the SNP to one without the
SNP. Genotypes were scored as 0/1/2 for homozygotes, heterozygotes, and
rare homozygotes, thus assuming an additive model. An approximate 
2
statistic was calculated as twice the natural logarithm of the likelihood ratio
with the SNP to the likelihood without the SNP, and a 1 degree of freedom
(d.f.) P value was calculated.
Admixture mapping was conducted on 1,450 individuals using the program
ADMIXMAP (17) to estimate the proportion of European admixture for each
subject. To avoid effects of linkage disequilibrium, markers were limited to
0.05-cM spacing, resulting in 4,486 markers. Markers were selected to optimize
the frequency difference between Caucasian and African (Yoruban) HapMap
samples. X chromosome markers were excluded.
RESULTS
We ﬁrst examined three traits, type 2 diabetes, age of type
2 diabetes diagnosis, and BMI, using variance components
linkage in 5,914 markers for 1,344 members of 530 fami-
lies. Given the close association of BMI with type 2
diabetes, the likely role in modifying age of type 2 diabetes
diagnosis, and as a surrogate for insulin resistance, our
primary goal was to determine whether BMI mapped to
type 2 diabetes or age of type 2 diabetes diagnosis (“di-
TABLE 1
Distribution of study participants by site
Site Individuals Sibling pairs
AL 50 33
AR 238 274
CH 411 432
CO 55 65
LA 126 113
LX 70 33
MD 101 45
NC 155 98
SC 137 54
SL 153 146
Totals 1,496 1,293
Data are n. Distribution of individuals and sibpairs by site, as listed
in RESEARCH DESIGN AND METHODS. AL, Birmingham, AL; AR, Little Rock,
AR; CH, Chicago; CO, Denver, CO; LA, Cedars Sinai, Los Angeles, CA;
LX, University of California, Los Angeles, CA; MD, Baltimore, MD;
NC, Raleigh-Durham, NC; SC, Charleston, SC; SL, St. Louis, MO.
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sites (Table 1). Characteristics of the study population are
shown in Table 2, and linkage results are shown in Fig. 1.
The LOD scores 1.5 for all three traits are summarized in
Table 3. Type 2 diabetes was most strongly linked to
chromosome 2 (124–132 Mb), with maxima of 4.53 at 127
cM and 2.98 at 108 cM, and this region showed suggestive
linkage to age of type 2 diabetes diagnosis (LOD 1.82 at 84
cM and 1.66 at 115 cM). Both type 2 diabetes and age of
type 2 diabetes diagnosis showed suggestive linkage also
to chromosome 13p (3–22 cM; LOD 2.42 for type 2 diabetes
and 2.46 for age of type 2 diabetes diagnosis). The stron-
gest linkage for age of type 2 diabetes diagnosis was on
chromosome 18p (LOD 2.96; 54–96 cM). Type 2 diabetes
also showed suggestive linkage to chromosome 7p (79 cM,
2.93), a region implicated previously (18). Other suggestive
type 2 diabetes peaks were on chromosome 4 (135 cM;
LOD 2.26), 11 (123 cM, 2.36), and 16 (56 cM, 2.43). The
chromosome 18 linkage for age of type 2 diabetes diagno-
sis corresponded with previous reports in Caucasians
(19,20). Best linkages for BMI were on chromosomes 1
(LOD 2.30, 69 cM), 18 (116 cM, at 2.45; telomeric to type 2
diabetes and age of type 2 diabetes diagnosis), and 21 (14
cM) but did not overlap with type 2 diabetes or age of type
2 diabetes diagnosis linkages except on chromosome 1
(70–90 cM and 123–130 cM; Table 3; Fig. 1).
As expected, NPL analysis of type 2 diabetes gave
overall smaller peaks and incomplete overlap with vari-
ance component scores. On chromosome 7 (27 cM; 1.73),
type 2 diabetes linkage corresponded to a region identiﬁed
in a preliminary report in African American Gullah-speak-
TABLE 2
Characteristics of study population
Variable Men Women Total
n (%) 521 (34.8) 975 (65.2) 1,496
Age (years) 53.3  13.1 53.8  12.8 53.6  12.9
Diabetes 406 (77.9) 802 (82.3) 1,208 (80.8)
Onset age of diabetes
diagnosis (years) 45.2  11.7 44.8  12.5 44.9  12.3
BMI (kg/m
2) 30.1  6.2 34.4  8.6 32.9  8.1
WHR 0.96  0.10 0.93  0.13 0.94  0.12
Fasting glucose (mmol/l) 8.77  4.53 8.59  4.05 8.65  4.23
Fasting insulin (pmol/l) 136  235 148  224 144  228
Data are n (%) or means  SD.
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FIG. 1. Linkage plots for variance component and NPL methods. Fig. 1 shows all linkage analyses conducted in one ﬁgure. As noted in the text,
numbers of individuals and numbers of markers varied across analyses. Variance component linkage for type 2 diabetes is black, for age of type
2 diabetes diagnosis is blue, and for BMI is green. LOD scores using MERLIN NPL scores are shown in red.
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LOD 1.63), 16 (51 cM; 1.84), and 22 (rs815550; 1.19) were
near variance component peaks (Fig. 1; supplementary
Table S2, available in the online appendix).
We performed ordered subset analysis on type 2 diabe-
tes NPL scores by ranking families (both from low to high
and high to low) by mean age of type 2 diabetes diagnosis,
BMI, waist, WHR, diabetes duration, and admixture. Loca-
tions with scores that increased signiﬁcantly are shown in
Table 4, with the most prominent regions in a subset of at
least 100 families on chromosomes 1 (30 cM; admixture),
3 (11 cM; age of type 2 diabetes diagnosis), 7 (131 cM;
WHR), and 14 (57 cM; duration of diabetes). Ranking
families by mean BMI produced no signiﬁcant result. Only
the region on chromosome 1 overlapped with a variance
component linkage signal (Table 4).
Admixture mapping provides an alternative to family-
based linkage to identify genes in recently admixed pop-
ulations (21,22). Although our SNP-based linkage map was
limited for admixture mapping by the relatively small
proportion of ancestrally informative markers, the large
number of markers nonetheless made mapping with the
ADMIXMAP program feasible. We tested autosomal mark-
ers at 0.05-cM intervals to avoid confounding by linkage
disequilibrium. Among the resulting 4,486 markers, the
strongest association was for SNP rs1565728 (chromo-
some 12, 90 cM; P  0.0003). No other marker approached
Bonferroni-corrected experiment-wide signiﬁcance (sup-
plemental data and supplementary Table S3, available in
the online appendix), and no marker that achieved nomi-
nal uncorrected signiﬁcance (P  0.05) mapped to a
linkage peak. Individual admixture estimates varied from
0.010 to 0.614 but with mean estimates by study site
ranging from 0.069 (South Carolina Gullah population) to
0.201 (Colorado) (supplemental data and supplementary
Table S4, available in the online appendix). Heterogeneity
of admixture proportions across sites was highly signiﬁ-
cant (
2  154.76, P  5  10
11; 10 df). Admixture
TABLE 3
Summary of linkage from variance component analysis
Chromosome Location Trait Maximum LOD SNP
1 32 Type 2 diabetes 2.27 Rs3766306
69 BMI 2.30 Rs1707302
114 AOD 1.98 Rs1215512
129 BMI 1.77 Rs338491
2 84 Type 2 diabetes 2.28 Rs1919481
108 Type 2 diabetes 2.98 Rs981525
115 AOD 1.66 Rs1567804
127 Type 2 diabetes 4.53 Rs925848
3 27 BMI 1.92 Rs2251166
150 BMI 1.54 Rs1479137
4 135 Type 2 diabetes 2.26 Rs426029
6 118 Type 2 diabetes 1.82 Rs2032558
7 79 Type 2 diabetes 2.93 Rs956523
135 BMI 1.84 Rs1862083
11 123 Type 2 diabetes 2.36 Rs1073636
12 27 Type 2 diabetes 2.14 Rs732868
13 4 Type 2 diabetes 2.33 Rs765244
16 Type 2 diabetes 2.42 Rs306395
22 AOD 2.45 Rs1572881/rs2491222
16 35 AOD 1.77 Rs30222
56 Type 2 diabetes 2.43 Rs11901
18 66 AOD 2.96 Rs920783
116 BMI 2.45 Rs1944566
20 62 Type 2 diabetes 1.77 Rs1406966
21 14 BMI 2.14 Rs6517799
22 31/41 Type 2 diabetes 1.68 Rs737622/rs715550
TABLE 4
OSA of type 2 diabetes
Chromosome Covariate Peak
Maximum
OSA score
Maximum unconditional
score Difference P value
Families and
ranking*
1 Admix. 30.00 4.11 2.33 1.79 0.0353 117/414
3 AOD 10.96 3.88 2.17 1.71 0.0279 175/404
4 AOD 109.31 3.93 1.80 2.13 0.0419 20/404
7 WHR 131.47 4.29 2.72 1.57 0.0326 211/371
11 AOD 104.00 4.10 2.58 1.53 0.0334 18/404
14 Duration 56.59 4.05 2.64 1.41 0.0297 222/351
17 Waist 56.10 3.95 1.43 2.52 0.0101 58/373
20 WHR 2.28 3.75 2.48 1.27 0.0372 33/371
Data are Z scores; P values are based on 500 permutations. Best signals from ordered subset analyses are shown. Admix, Caucasian
admixture; duration, duration of diabetes; waist, waist circumference. *Families ranked from lowest to highest mean covariate value, ;
families ranked from highest to lowest mean value, .
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(P  0.01) and age of type 2 diabetes diagnosis (P  0.003)
but had no effect on BMI (P  0.95).
DISCUSSION
Considerable progress has been made in the identiﬁcation
of type 2 diabetes susceptibility genes for individuals of
European ancestry. Nonetheless, only a small portion of
the genetic risk has been explained, and of the 18 reported
susceptibility genes (4), only TCF7L2 shows any evidence
for a role in African-derived populations (5). Thus, most of
the susceptibility genes in high-risk ethnic groups remain
to be identiﬁed. Genome-wide association studies in pop-
ulations of African descent may identify a subset of these
genes, but a much larger number of SNPs will be required
to overcome lower levels of linkage disequilibrium, with
accompanying difﬁculties in separating real signals from
noise in populations that are readily available. Family-
based linkage studies, particularly SNP-based methods
with higher information content, thus remain an important
alternative. Based on European data, linkage peaks are
unlikely to represent single common variants of large
effect sizes. Instead, these peaks likely represent multiple
rare variants of large effect, copy number polymorphisms,
or multiple common variants that together provide a
linkage signal. Only the latter model is amenable to
genome-wide association studies, but even for such vari-
ants, the additional information of linkage studies may be
essential to select signiﬁcant associations from the large
number of nominally associated SNPs.
Previous studies of populations of African descent have
been limited. As of this writing, no genome-wide associa-
tion studies of African-based populations have been re-
ported, and most European susceptibility loci do not
appear to be important in African American populations
(5). Among previous linkage studies, Sale et al. (8) used a
microsatellite map to analyze 675 individuals in 247 fami-
lies ascertained primarily for diabetic renal disease. The
strongest signal from that study (chromosome 6q, 163 cM)
is considerably telomeric to our strongest chromosome 6
peak (LOD 1.82 at 118 cM), whereas the second best signal
from that study (chromosome 22, 32 cM, LOD 1.33) is in
the same location as a minor peak in our current study (33
cM, LOD 1.68). Our strongest signals do not overlap with
those found by Sale et al., however. A microsatellite scan
in West African families (9) reported signals on chromo-
some 20 (LOD 1.8; 60–78 cM), which overlapped with a
minor peak of similar size in our study at rs1406966 (LOD
1.77; 62 cM). A second minor peak on chromosome 4 from
the West Africa study (LOD 1.37, 125 cM) also overlapped
with a peak on chromosome 4 (135 cM; LOD 2.26) in our
study. The African American families in the report of Ehm
et al. (7) are entirely contained in the present multicenter
study, and thus, any overlap in linkage signals would not
be independent. More recently, Sale et al. (18) analyzed
471 individuals from the Gullah-speaking African Ameri-
can population of South Carolina for the same SNP
markers as the present study. Chromosome 7 linkage to
type 2 diabetes from that study overlaps with both NPL
and variance component peaks near 27, 40, and 78 cM
reported here (18) (M. Sale, personal communication).
Because some of the GENNID samples included Gullah-
speaking families from South Carolina, we repeated our
chromosome 7 analysis excluding all samples from South
Carolina. The maximum LOD score dropped from 2.93 to
2.03, consistent with a contribution to the total score from
the South Carolina samples. Whereas Sale et al. (18) found
chromosome 7 to be most strongly implicated in early-
onset type 2 diabetes, ordered subset analyses in our
sample with families ranked by age of type 2 diabetes
diagnosis implicated no peak in this region.
In a recently published meta-analysis of 23 microsatel-
lite linkage scans across ethnic groups that included both
Chicago and Arkansas African American GENNID families
(23), ﬁve regions of linkage overlapped with the current
study: chromosomes 4 (135 cM), 6 (118 cM), 16 (56 cM), 20
(62 cM), and 22 (40 cM). Despite the partial overlap in
samples, the only possible overlap in linkage signals
between our study and the African American subgroup
from the meta-analysis was on chromosome 16 (33–66
cM). Other African/African American peaks from the meta-
analysis (chromosomes 4, 6, 10, and 14) were not observed
in the present study.
Simulation studies and comparisons of microsatellite
and SNP-based linkage scans have suggested that scans
based on 10,000 SNPs provide superior information to the
standard 10-cM microsatellite scans for diseases including
prostate cancer (24), rheumatoid arthritis (25,26), and
bipolar disorder (27). Each of the earlier studies used the
10,000-SNP Affymetrix platform, whereas we used the
5,914-SNP Illumina platform. We compared the informa-
tion content between the Illumina SNP mapping panel and
the earlier CIDR microsatellite panel (8) using Arkansas
families that had been typed for both marker sets. The
information content for all chromosomes was increased
from 50 to 60% for the microsatellite scans to 80% for the
SNP scan (supplemental data and supplementary Fig. S1).
This increased information content would be expected to
generate a larger number of signiﬁcant or suggestive
linkage peaks, narrower and better deﬁned peaks, and
perhaps could explain the lack of overlap with earlier,
generally smaller linkage scans in African American
families.
The typing of 5,914 SNPs at relatively even intervals
allowed us to also map by admixture. In contrast to
linkage, admixture mapping depends on the presence of
extended haplotypes deriving from parental populations to
map a disease such as type 2 diabetes that is more
prevalent in the African than European populations. This
approach has more power than linkage or genome scan
approaches to identify genes that derive primarily or
entirely from either the African or European populations
when the markers also show large frequency differences
between populations. Admixture mapping would not be a
powerful method to identify susceptibility loci that are
common and of similar frequency in both ethnic groups
(22), and power would be reduced if marker frequencies
are similar between parental populations. Admixture map-
ping has recently been used successfully in mapping
hypertension susceptibility genes (28,29). The marker set
in the current study was not speciﬁcally designed for
admixture mapping, but the amount of data generated was
sufﬁcient to easily identify admixture. We found a strong
negative correlation between European admixture and
both type 2 diabetes risk and age of type 2 diabetes
diagnosis. Furthermore, our data easily demonstrated sig-
niﬁcant heterogeneity in the amount of admixture across
centers. Nonetheless, 10% of the markers showed a
minor allele frequency difference between Yoruban and
Caucasian HapMap samples exceeding 0.5. Thus, a specif-
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and/or more signiﬁcant signals.
Our strongest signal was at rs1565728 on chromosome
12 (90 cM). When we examined different combinations of
markers in this region, we obtained P values from 0.00003
to 0.03, suggesting that no single marker was responsible
for the signal. The only gene in the immediate vicinity of
this marker is the transcription factor, E2F7, which is
involved in cell cycle regulation but is expressed at low
levels in most tissues (30). However, admixture and link-
age mapping peaks did not overlap, and no admixture
signal achieved genome-wide signiﬁcance (supplementary
Table S2). Chromosome 1 marker rs1007460, the second
strongest admixture signal (supplementary Table S2), was
close to a well-replicated linkage signal on chromosome
1q21-q24 (31). These ﬁndings will require follow-up with
markers speciﬁcally selected for large differences in allele
frequency between ancestral populations.
We tested for family-based association with type 2
diabetes, BMI, and age of type 2 diabetes diagnosis,
although recognizing the limitations of the relatively low-
density SNP linkage panel. No SNP attained Bonferroni-
corrected signiﬁcance (supplementary Table S5, available
in the online appendix); but rs741923 on chromosome 19
(P  0.0001) was suggestive for association with type 2
diabetes; and SNPs rs1459085 (chromosome 5; P 
0.0002), rs729958 (chromosome 9, P  0.00005), and
rs1941487 (chromosome 18, P  0.0002) were suggestive
for association with diabetes age of type 2 diabetes
diagnosis. SNPs on chromosomes 2 (rs838715, P  0.0001)
and 8 (rs1483457, P  0.0001) showed suggestive associ-
ations with BMI. SNPs rs1459085 (chromosome 5) and
rs729958 (chromosome 9) were associated with both type
2 diabetes and age of type 2 diabetes diagnosis. Although
association and linkage signals generally did not overlap,
rs1051783 (type 2 diabetes, P  0.002) was within the
chromosome 2q linkage peak and near gene MFSD9,
which is not an obvious candidate. Several SNPs on
chromosome 6q21 (113–118 cM) were modestly associated
with type 2 diabetes (P  0.002) in a region of modest
linkage (LOD 1.54). Among the known genes in this region
are peptidylprolyl isomerase like 6 and zinc ﬁnger protein
ZBTB24; neither is an obvious diabetes candidate gene.
SNP rs2491222 (P  0.0005 with type 2 diabetes) was
under the chromosome 13 linkage peak for type 2 diabetes
and age of type 2 diabetes diagnosis and within FLT3,
which encodes a tyrosine kinase with known roles in
hematopoiesis and leukemias. SNP rs11901 (chromosome
16) showed linkage to type 2 diabetes (LOD 1.76) and
association with type 2 diabetes and age of type 2 diabetes
diagnosis (P  0.002) and is upstream of the serine/
threonine kinase, TAOK2, which acts in the Jun NH2-
terminal kinase mitogen-activated protein (MAP) kinase
pathway by activating upstream MAP kinases (MKK)
MKK3 and MKK6.
Three peaks were most prominent in the linkage analy-
sis (Fig. 1): chromosome 2 extending from 41 to 121 Mb
and encompassing 354 genes (498 unique transcripts),
chromosome 13 from 18 to 31 Mb and encompassing 73
genes (89 unique transcripts), and chromosome 18 from 27
to 64 Mb and encompassing 130 genes (178 unique tran-
scripts). Within these 557 genes are many strong candi-
dates for type 2 diabetes. On chromosome 2, candidates
include hexokinase 2, transcription factor TCF7L1, vesic-
ular transport proteins VAMP5 and VAMP8, liver fatty
acid-binding protein FABP1, dual-speciﬁcity phospha-
tase DUSP2, diabetes-related ankyrin repeat protein
ANKRD23, and potential insulin signaling molecules
MAP4K4 and INPP4A, as well as INSIG2 and STEAP3.O n
chromosome 13, candidates include CDK8, IPF1, and TNF
superfamily member TNFRSF19. The chromosome 18
peak included another TNF superfamily member,
TNFRSF11a, as well as MC4R, TCF4, phosphoinositide-3-
kinase, class 3, and phosphatidylinositol glycan anchor
biosynthesis. Only IPF1 was previously evaluated in Afri-
can Americans (32,33) but was not found to be associated
with type 2 diabetes.
In addition to the limitations noted above, our analysis
of age of diagnosis was based on historical data. Even
when obtained by standardized questionnaire, historical
age of type 2 diabetes diagnosis is inexact and likely not an
accurate reﬂection of the true age of onset. Nonetheless,
this trait showed 60% heritability with similar values
across centers and good correspondence with diabetes as
a dichotomous trait.
In summary, using a large multicenter collection of
nuclear families, a SNP-based linkage panel, and analytical
methods based on variance component, admixture map-
ping, and ordered subsets, we have identiﬁed multiple
regions of interest. Phenotypes of type 2 diabetes and
diabetes age of diagnosis frequently mapped to the same
locations, lending additional conﬁdence to these results.
Based on current understandings of complex disease
pathogenesis, the majority of these regions probably rep-
resent collections of causative variants, rather than single
SNPs or genes that can explain the linkage signal. Dense
maps suitable for narrowing linkage signals, further ex-
ploring admixture mapping, and testing family-based asso-
ciation using maps that tag all variants in known genes will
be logical steps. With most genetic risk factors yet to be
discovered, these studies will undoubtedly complement
other genome-wide association efforts in identifying those
genes that contribute to diabetes in African Americans and
other populations.
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